Navigation Links
Medtronic Infuse Bone Graft Failure Allegation Lawsuits Update: New Legal Consultations Available Over Alleged Medical Malpractice

San Diego, CA (PRWEB) June 11, 2013

Resource4thePeople, in its latest update to consumers affected by operations involving medical devices, today announced new legal options that are being offered involving alleged serious side effects involving Medtronic Infuse bone grafts.

The medical devices have been attracting consumer interest in the wake of a Class 1 Recall by the Food and Drug Administration* and a highly critical report** from a U.S. Senate committee that raised concerns about conflicts of interest because of payments the company made to medical researchers and physicians.

"In response to confusion cited by consumer inquiries, there are now available free consultations involving allegations of medical malpractice in addition to those involving alleged side effects from the Medtronic Infuse Bone Graft," said Resource4thePeople.

"We are finding that some consumers are inquiring about allegations that they underwent surgeries that were not necessary in which they received Medtronic Infuse Bone Graft implants. We are also finding that some patients are alleging that they have had serious health problems as a result of these implants. These may be separate legal issues."

Resource4thePeople also said that it is expanding its national network of legal assistance to now provide these complimentary consultations for both types of inquiries.

“In addition, we will also continue to provide regular updates providing these consumers with information about the legal rights they may have to pursue compensation over allegations of Medtronic Infuse Bone Graft side effects," said Resource4thePeople.

"Among these updates will be the results of an Infuse study conducted by researchers at Yale University, which will provide an independent overview of bone graft products."

HealthPointCapital, in a May 23, 2013 posting,*** said the findings of the review are expected to be released this month. The study was commissioned after stories were published in 2011 in The Spine Journal**** revealing that Infuse bone graft complications were being underreported.

Resource4thePeople said it will continue to track the progress of the review by Yale researchers and post the results as soon as they are made public.

“This will continue to be an area of prime focus for us as we provide consumers legal options involving allegations that the Medtronic Infuse Bone Grafts may have caused serious, life-threatening health problems,” said Resource4thePeople.

“Among the allegations we are investigating are claims from consumers alleging that the Medtronic Infuse Bone Grafts were used improperly in medical operations and caused serious side effects to patients.”

Resource4thePeople also said that its national network of attorneys will continue to offer free consultations to consumers who are alleging they may have suffered severe back and leg pain, infections, bone deterioration, sterility and cancer, among other problems.

In the FDA’s Feb. 16, 2011 Class 1 Recall* of Medtronic Infuse Bone Graft pumps and refill kits, the FDA said the products "may result in patient harm, serious injury, and/or death due to drug overdose or underdose.”

Class I recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of these products will cause serious adverse health consequences or death.

Resource4thePeople also notes that a federal lawsuit***** was filed in March in the Southern District of Ohio against Medtronic Inc. and an Ohio surgeon who, according to complaint, was a paid Medtronic consultant in addition to his professional duties.

The lawsuit includes allegations that 88 patients are claiming that underwent spine surgeries involving bone protein that they did not consent to and have suffered detrimental side effects for which they are seeking compensation.

The lawsuit claims that "medically unnecessary, experimental spine surgeries" were performed "using falsely and improperly marketed Medtronic medical devices and drugs," according to allegations contained in the court file.

Resource4thePeople also said that the allegations filed in the new lawsuit raise more questions about the relationships between physicians and Medtronic over fees paid to the doctors that have come under criticism** from U.S. Senate Finance Committee investigators.

“The revelations included in the Oct. 25, 2012 report by the Senate Finance Committee involving payments to doctors and the downplaying of dangerous side effects from this medical device have raised serious questions among patients who underwent these surgeries and have contacted us," said Resource4thePeople.

Resource4thePeople said that over the last few months such inquiries have increased as a result of news media reports about the findings of the committee’s investigation into Medtronic’s spending of millions of dollars to doctors and researchers in return for studies favorable to the Infuse device.

The Medtronic Infuse bone graft was approved by the Food and Drug Administration as a sanctioned medical device designed to stimulate spinal bone growth in patients suffering from lower spine degenerative diseases.

*****Case # 1:13cv0202 U.S. District Court, Southern District of Ohio

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Medtronic Infuse Bone Graft Questioned As Allegations Unfold – Bisnar
2. Chase Attorneys Offer Free Consultations
3. Medtronic Voted the Most Sought-After Employer by Community
4. Medtronic Infuse bone-graft lawsuit consultation referrals offered by Resource4thePeople
5. 2013 Cases Involving Medtronic Infuse Bone Graft Failure Allegations Now Being Investigated by Resource4thePeople Lawyers
6. Medtronic Infuse Bone Graft Lawsuits: Bernstein Liebhard LLP Notes New Report Predicting Hundreds of Medtronic Infuse Lawsuits
7. Medtronic Infuse Bone Graft Failure Allegation Lawsuits Information Bank for Consumers Now Available through Resource4thePeople
8. Medtronic Infuse Lawsuit News: Bernstein Liebhard LLP Awaits Expected Release of Medtronic-Commissioned Analysis of Infuse Bone Graft Trials
9. Medtronic Takes the Lead in the US Spinal Implant Market, Reports iData Research
10. Medtronic Infuse Lawsuit News: Parker Waichman LLP Alerts the Public to the June Release of Yale’s Infuse Bone Graft Study
11. Ready for debut: Fruit-juice-infused chocolate with 50 percent less fat
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: